

DAFTAR PUSTAKA

- Abdel-Misih, S. R. Z. and Bloomston, M. (2010) 'Liver Anatomy', *Surgical Clinics of North America*. Elsevier Ltd, 90(4), pp. 643–653. doi: 10.1016/j.suc.2010.04.017.
- Abbas, A., Medvedev, S., Shores, N., Bazzano, L., Dehal, A., Hutchings, J. (2014). 'Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective', *Digestive Diseases and Sciences*, 59(11), pp. 2813-2820.
- Alison M. R., Nicholson, L. J., Lin W. R. (2011) 'Chronic inflammation and hepatocellular carcinoma', *Recent Results Cancer Res*, 185, pp.135-148. doi: 10.1007/978-3-642-03503-6_8.
- Anis, M and Irshad. (2011) 'Imaging of Hepatocellular Carcinoma : Practical Guide to Diffeerential Diagnosis', *liver.theclinics.com*, 15, pp. 335–352. doi: 10.1016/j.cld.2011.03.014.
- Appel-da-Silva, M.C., Miozzo S, Dossin I, Tovo C, Branco F, Mattos A. (2016) 'Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study', *World J Gastroenterol*, 22(46), pp 10219-10225. doi: [10.3748/wjg.v22.i46.10219](https://doi.org/10.3748/wjg.v22.i46.10219).
- Arslanoglu, A., Seyal, A., Sodagari, F., Sahin, A., Miller, F., Salem, R. and Yaghmai, V. (2016). 'Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review', *American Journal of Roentgenology*, 207(5), pp.W88-W98.
- Bagirsakci E., Şahin E, Atabey N, Erdal E, Guerra V, Carr B. (2017) 'Role of albumin in growth inhibition in hepatocellular carcinoma', *Oncology*, 93(2), pp. 136-142. doi: 10.1159/000471807.
- Bosetti, C., Turati, F. and La Vecchia, C. (2014). 'Hepatocellular carcinoma epidemiology', *Best Practice & Research Clinical Gastroenterology*, 28, pp.753-770
- Bruix, J. and Sherman, M. (2011) 'Management of hepatocellular carcinoma: An update', *Hepatology*, 53(3), pp. 1020–1022. doi: 10.1002/hep.24199.
- Carr, B., Akkiz, H., Guerra, V. (2018) 'C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors', *Clin Pract (Lond)*, 15(Spec Issue), pp.625-634
- Cartier, V. and Aubé, C. (2019). *Diagnosis of hepatocellular carcinoma*. *Diagnostic and Interventional Imaging* (2014) 95, 709—719.

- Cervoni, J. P., Thévenot T, Weil D, Muel E, Barbot O, Sheppard F *et al.* (2012). 'C-reactive protein predicts short-term mortality in patients with cirrhosis', *J Hepatol*, 56, pp. 1299-304.
- Child, C. G. and Turcotte, J. G. (1964) 'Surgery and portal hypertension', *Major Probl Clin Surg*, 1, 1-85.
- Cholankeril, G., Patel, R., Khurana, S. and Satapathy, S. (2017) 'Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management', *World Journal of Hepatology*, 9(11), p.533.
- Chung K. M., Chien T, Chuang S, Wu H, Sheu M, Lin C *et al.* (2014). 'High pre-operative serum aminotransferase levels predict local recurrence after curative resection of hepatocellular carcinoma', *Advances in digestive medicine*, 1(1), pp.14-20.
- Clyne, B., Olshaker, J. (1999). 'The C-reactive protein', *The Journal of Emergency Medicine*, 17(6), pp.1019-1025
- El-Serag, H. B., Marrero, J. A., Rudolph, L. and Reddy, K. R. (2008) 'Diagnosis and Treatment of Hepatocellular Carcinoma', *Gastroenterology*, 134(6), pp. 1752–1763. doi: 10.1053/j.gastro.2008.02.090.
- El-Serag, H. B. and Rudolph, K. L. (2007) 'Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis', *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
- Ellis, H. (2011) 'Anatomy of the liver', *Surgery*. Elsevier Ltd, 29(12), pp. 589–592. doi: 10.1016/j.mpsur.2011.09.012
- Fabris, C., Pirisi M, Soardo G, Falletti E, Pezzetta F, Vitulli D *et al.* (1994) 'Value of serum c-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis', *J Cancer Res Clin Oncol*, 120(4): pp.229-232.
- Farazi, P. A. and DePinho, R. A. (2006) 'Hepatocellular carcinoma pathogenesis: From genes to environment', *Nat Rev Cancer*, 6(9), pp. 674–687. doi: 10.1038/nrc1934.
- Fenoglio, L. (2013) 'Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases', *World J Gastroenterol*, 19(21), pp. 3207-3216. doi: 10.3748/wjg.v19.i21.3207.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A. and Pawlik, T. M. (2016) 'Hepatocellular carcinoma: From diagnosis to treatment', *Surgical Oncology*. Elsevier Ltd, 25(2), pp. 74–85. doi: 10.1016/j.suronc.2016.03.002.
- Greenland, S., *et al.* (2016) 'Statistical tests, p values, confidence intervals, and

- power: a guide to misinterpretations', *Eur J Epidemiol*, 31: 337-350.
- Hann H. W., Wan S, Myers R, Hann R, Xing J, Chen B *et al.* (2012) Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients', *PLoS One*, 7(10), pp.e47687. doi: 10.1371/journal.pone.0047687.
- Hennedige, T. and Venkatesh, S. (2012) 'Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring', *Cancer Imaging*, 12(3), pp.530-547.
- Jang, W. J, Oh B, Kwon J, You C, Chung K, Kay C *et al.* (2012) 'Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma', *Cytokine*, 60(3): pp. 686-693. doi: 10.1016/j.cyto.2012.07.017
- Kao, W. Y., Su C, Chiou Y, Chiu N, Liu C, Fang K *et al.* (2017) 'Hepatocellular carcinoma: nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation', *Radiology*, 285(2). doi: <https://doi.org/10.1148/radiol.2017162382>.
- Katyal, S., Oliver, J. H., Peterson, M. S., Ferris, J. V., Carr, B. S., Baron, R. L. (2000) 'Extrahepatic metastases of hepatocellular carcinoma', *Radiology*, 216(3), pp. 698-703.
- Kim, W. R. (2005) 'The use of decision analytic models to inform clinical decision making in the management of hepatocellular carcinoma', *Clin Liver Dis.* (9(2), pp. 225-234.
- Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Tanaka, K., Fushiya, N., Koike, K., Nishino, H., Matsushima, M. and Tajiri, H. (2014) 'The Addition of C-Reactive Protein to Validated Staging Systems Improves Their Prognostic Ability in Patients with Hepatocellular Carcinoma', *Oncology*, 86(5-6), pp.308-317.
- Lee C, Chan K, Lee C, Yu M, Lee W, Wu T *et al.* Hepatic Resection for Hepatocellular Carcinoma With Lymph Node Metastasis: Clinicopathological Analysis and Survival Outcome. *Asian Journal of Surgery*. 2011;34(2):53-62
- van Leuuwen, D. J., Schumate, C. R. (2000) 'Space-occupying lesions of the liver'. In: *Imaging in hepatobiliary and pancreatic disease: a practical clinical approach*. London: WB saunders.
- Liovet, J.M., Fuster, J., Bruix, J. (2004) 'Barcelona-Clinic Liver Cancer group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma', *Liver transplant*. 2(1), pp. S115-120.
- Liu, P. H., Huo, T. I., Miksad R. (2018) 'Hepatocellular carcinoma with portal vein tumor involment: best management strategies', *Seminars in Liver Disease*,

38(03), 242-251. doi: 242–251. doi:10.1055/s-0038-1666805 .

- Marrero, J., Kulik, L., Sirlin, C., Zhu, A., Finn, R., Abecassis, M., Roberts, L. and Heimbach, J. (2018) 'Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases', *Hepatology*, 68(2), pp.723-750.
- McEvoy, S., McCarthy, C., Lavelle, L., Moran, D., Cantwell, C., Skehan, S., Gibney, R. and Malone, D. (2013). 'Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases', *RadioGraphics*, 33(6), pp.1653-1668
- Mittal, S. and El-Serag, H. (2013) 'Epidemiology of Hepatocellular Carcinoma', *Jl of Clin Gastroenterology*, 47, pp.S2-S6.
- Nonami, T., Yokoyama I, Iwatsuki S, Starzl T. (1992) 'The incidence of portal vein thrombosis at liver transplantation', *Hepatology*, 16, pp. 1195-1198. doi: 10.1002/hep.1840160515.
- Padhya, K. T., Marrero, J. A. and Singal, A. G. (2013) 'Recent advances in the treatment of hepatocellular carcinoma', *Curr Opin Gastroenterol*, 29(3), pp. 285–292. doi: 10.1097/MOG.0b013e32835ff1cf.
- Peng, Y., Qi, X., Guo, X. (2016) 'Child-Pugh versus MELD score for the assesment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies', *Medicine*, 95(8), pp.e2877. doi: 10.1097/MD.0000000000002877.
- Puoti C. (2018) 'New insights on hepatocellular carcinoma: epidemiology and clinical aspects', *Hepatoma Res*, 4, pp.57. doi: [10.20517/2394-5079.2018.67](https://doi.org/10.20517/2394-5079.2018.67)
- Sanai, F. M., Sobki S, Bzeizi K, Shaikh S, Alswat K, Al-Hamoudi W *et al.* (2010) 'Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients', *Dig Dis Sci*, 55(12): pp.3568-75. doi: 10.1007/s10620-010-1201-x.
- Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) 'The Etiology of Hepatocellular Carcinoma and Consequences for Treatment', *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.
- Sastroasmoro, S. & Ismael, S. 2011. Usulan Penelitian. In S. Sastroasmoro & S. Ismael, eds. *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, pp. 31–63.
- Sieghart, W., Pinter M, Hucke F, Graziadei I, Schöniger-Hekele M, Müller C *et al.* (2012) 'Single determination of C-reactive protein at the time of diagnosis

predicts long-term outcome of patients with hepatocellular carcinoma', *Hepatology*, 57(6). doi: 10.1002/hep.26057.

Sproston, N. and Ashworth, J. (2018) 'Role of C-Reactive Protein at Sites of Inflammation and Infection', *Frontiers in Immunology*, 9.

Suner, A., I. Carr, B., Akkiz, H., Uskudar, O., Kuran, S., Tokat, Y., *et al.* (2018) 'Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics', *Journal of Translational Science*, 5(3).

Suner, A., Carr, B., Akkiz, H., Karakülah, G., Üsküdar, O., Yalçın, K., *et al.* (2018) 'C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma', *Oncology*, 96(1), pp.25-32.

Tang, A., Hallouch, O., Chernyak, V., Kamaya, A. and Sirlin, C. (2017) 'Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis', *Abdominal Radiology*, 43(1), pp.13-25.

Venook, A., Papandreou, C., Furuse, J. and Ladron de Guevara, L. (2010) 'The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective', *The Oncologist*, 15(Supplement 4), pp.5-13.

Villanueva, A. (2019) 'Hepatocellular Carcinoma', *New England Journal of Medicine*, 380(15), pp.1450-1462.

Waghray A., Murali A. R., Menon K. V. N. (2015) 'Hepatocellular carcinoma: From diagnosis to treatment', *World J Hepatol*, 7(8), pp. 1020-1029. doi: 10.4254/wjh.v7.i8.1020.

Waller, L. P., Deshpande, V. and Pysopoulos, N. (2015) 'Hepatocellular carcinoma: A comprehensive review', *World J Hepatol*, 7(26), pp. 2648–2663. doi: 10.4254/wjh.v7.i26.2648.

Wang, C., Sun, C. (2009) 'C-reactive protein and malignancy: Clinico-pathological association and therapeutic implication', *Chang Gung Med J*, 32(5), pp.471-82.

Wang X. P., Mao M, He Z, Zhang L, Chi P, Su J *et al.* (2017) 'A retrospective discussion of the prognostic value of combining prothrombin time (PT) and fibrinogen (Fbg) in patients with hepatocellular carcinoma', *J Cancer*, 8(11): 2079-2087. doi: 10.7150/jca.19181.

Watson J., Salisbury C., Banks J., Whiting P., Hamilton W. (2019) 'Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records', *British Journal of Cancer*, 120: pp.1045-1051.

Willatt, J., Ruma, J., Azar, S., Dasika, N. and Syed, F. (2017) 'Imaging of

hepatocellular carcinoma and image guided therapies - how we do it', *Cancer Imaging*, 17(1).

- Xia, F., Wu L, Lau W, Li G, Huan H, Qian C *et al.* (2014) 'Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis', *PLoS One*, 9(4).
- Yapali, S. and Tozun, N. (2018) 'Epidemiology and viral risk factors for hepatocellular carcinoma in the Eastern Mediterranean countries', *Hepatoma Research*, 4(6), p.24.
- Yu, L. X., Ling Y., Wang H. Y. (2018) 'Role of nonresolving inflammation in hepatocellular carcinoma development and progression', *NPJ Precision Oncology*, 2(6). doi:10.1038/s41698-018-0048-z.
- Zanetto A., Campello E, Spiezia L, Burra P, Simioni P, Russo F *et al.* (2018) 'Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma', *Cancers*, 10(11), pp. 450. doi: 10.3390/cancers10110450
- Zheng, Z., Zhou, L., Gao, S., Yang, Z., yao, J. and Zheng, S. (2013) 'Prognostic Role of C-Reactive Protein in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis', *International Journal of Medical Sciences*, 10(6), pp.653-664.
- Zhou L., Wang S, Chen S, Qu Q, Rui J *et al.* (2018) 'Prognostic value of ALT, AST, and AAR in hepatocellular carcinoma with B-type hepatitis associated cirrhosis after radical hepatectomy', *Clin Lab*, 64(10), pp.1739-1747. doi: 10.7754/Clin.Lab.2018.180532.